SM
Summit Therapeutics
SMMT · NASDAQ
$16.90 -3.68% (-$0.65)
1M +32.76%
Market Cap $13.5B
P/E Ratio -
Div. Yield -
ROE 204.33%
Bulios Fair Price
$9.24
45.3% downside
Current Price
$16.9
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SMMT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 21.40x
PEG N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 67.93%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 113.81%
ROIC 134.14%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 6.96x
Debt/Equity 0.03x
Debt/Assets N/A
Stability
19 /100
Unstable Profitable years 0
Beta -1.24x
EPS volatility 275.36%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SMMT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Robert W. Duggan
Employees
265
Headquarters
Miami
Upcoming events
19 OCT
Earnings
Upcoming earnings report